Key result
Myxofibrosarcoma linked to ~12% lower absolute overall survival versus all extremity STS.
Why the study?
The low incidence of myxofibrosarcoma limits high-power studies, and its demographic and prognostic factors compared to all extremity soft tissue sarcomas are not well understood.
Cohort (n=13,764)
Yes
Myxofibrosarcoma has distinct demographic characteristics and worse overall survival compared to other extremity soft tissue sarcomas.
Answers are grounded in this paper and cite their sources.
MFS portends worse survival, especially in older adults; leaves open whether histology-specific strategies improve outcomes beyond current STS care.
Background: The low incidence of myxofibrosarcoma (MFS) makes high power studies difficult to perform. Demographic and prognostic factors for MFS and how they differ from all extremity soft tissue sarcomas (STS) are not well understood. The purpose of this study was to characterize a large cohort of patients with MFS and evaluate epidemiologic and survival factors when compared to all STS. Materials and methods: We performed a retrospective review of the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2015 to identify 1,440 patients diagnosed with MFS and 12,324 with STS. Survival curves were creased using Kaplan-Meier, and Cox regression analyses were performed to identify hazard ratios (HRs). Results: Overall survival was greater for STS than MFS (79% vs. 67%). Patients with MFS had a higher average age at diagnosis than STS (62 vs. 56), and older age was strongly associated with decreased survivorship for MFS (HR = 7.94). A greater proportion of patients under 30 diagnosed with MFS were female when compared to STS (49.6% vs. 45.4%). The incidence of MFS and STS increased over the 15-year period, with MFS increasing at a greater rate than STS (1.25% vs. 2.59%). Survival increased for patients diagnosed after 2008 for both STS (9.4%) and MFS (13.2%). Conclusions: There are differences between patient demographics and survival factors when comparing MFS to all STS. Monitoring changes in demographic and survival trends for rare STS subtypes like MFS is important to improve diagnostic algorithms and treatment options.
No takes yet. Share an insight, caveat, or question.
Dahl et al. (2023) conducted a cohort in Appendicular myxofibrosarcoma (n=13,764). Myxofibrosarcoma (MFS) vs. All extremity soft tissue sarcomas (STS) was evaluated on Overall survival. Patients with myxofibrosarcoma had lower overall survival compared to those with all extremity soft tissue sarcomas, with older age strongly decreasing survivorship.
Synapse has enriched 10 related papers. Consider them for comparative context: